Key result
Nationwide AMA hypertension program adoption is projected to prevent ~601,000 CVD events over a decade.
Why the study?
The 10-year health and economic impacts of widely adopting the AMA's Measure Accurately, Act Rapidly, and Partner with Patients Hypertension quality improvement program were unknown.
Does the Measure Accurately, Act Rapidly, and Partner with Patients Hypertension program improve blood pressure control, reduce cardiovascular events, and lower healthcare costs in patients with hypertension?
Does the Measure Accurately, Act Rapidly, and Partner with Patients Hypertension program improve blood pressure control, reduce cardiovascular events, and lower healthcare costs in patients with hypertension?
Nationwide implementation of a structured hypertension quality improvement program is projected to substantially reduce cardiovascular events and mortality while yielding net healthcare savings over 10 years.
Model projections support piloting MAP hypertension program rollout; prospective studies needed to confirm real-world gains.
INTRODUCTION: This study uses microsimulation to estimate 10-year health and economic outcomes that may be achieved by widely adopting the American Medical Association's Measure Accurately, Act Rapidly, and Partner with Patients Hypertension quality improvement program. METHODS: A microsimulation model was adapted to conduct what-if analyses for adopting the Measure Accurately, Act Rapidly, and Partner with Patients Hypertension program nationwide and in care delivery systems of varying size. The analysis was conducted in 2020-2024, and the microsimulation model was constructed using various data sources from 1948 to 2019. Modeled outcomes over 10 years included prevalence of systolic blood pressure ≥140 mmHg, incidence of cardiovascular disease events and cardiovascular disease-related mortality, averted medical costs by payer in 2021 U.S. dollars, and net costs. RESULTS: For patients with hypertension over 10 years, nationwide adoption of the Measure Accurately, Act Rapidly, and Partner with Patients Hypertension program was predicted to improve mean blood pressure control by 4.3% and prevent 601 thousand cardiovascular disease events and 120 thousand cardiovascular disease deaths. Most of the estimated $17.9 billion in averted disease costs were observed in patients with Medicare. Total costs associated with implementing the Measure Accurately, Act Rapidly, and Partner with Patients Hypertension program totaled $12.6 billion, resulting in a predicted $5.3 billion in net savings to the healthcare sector over 10 years. Small and large care delivery organizations could economically benefit from implementing the Measure Accurately, Act Rapidly, and Partner with Patients Hypertension program at varying levels (5%-50%) of shared cost savings from payers. CONCLUSIONS: There is promise for quality improvement programs targeting blood pressure management, but more research is needed to affirm the assumptions and findings of this analysis.
No takes yet. Share an insight, caveat, or question.
Dehmer et al. (2025) studied Hypertension. Measure Accurately, Act Rapidly, and Partner with Patients Hypertension program was evaluated on Prevalence of systolic blood pressure ≥140 mmHg, incidence of cardiovascular disease events and mortality, and costs. Nationwide adoption of the Measure Accurately, Act Rapidly, and Partner with Patients program was predicted to prevent 601,000 CVD events and yield $5.3 billion in net savings over 10 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: